Nanopore is a biotech company developing and selling nanopore sequencing products (including the portable DNA sequencer, MinION) for the direct, electronic analysis of single molecules.
Nanopore aims to disrupt the paradigm of biological analysis by making high performance, novel DNA/RNA sequencing technology that is accessible and easy to use.
Nanopore was founded in 2005 as a spin-out from the University of Oxford by Hagan Bayley, Gordon Sanghera, and Spike Willcocks. The company is headquartered in Oxford, Oxfordshire, with satellite offices in Cambridge (UK), New York, Cambridge, San Francisco (US), Singapore, Shanghai, Beijing, and a broader commercial presence that includes Japan, Germany, France and India.
Nanopore has developed a new generation of DNA/RNA sequencing technology. It is the only sequencing technology that offers real-time analysis (for rapid insights), in fully scalable formats from pocket to population scale, that can analyse native DNA or RNA and sequence any length of fragment to achieve short to ultra-long read lengths.
Nanopore' novel, electronics-based DNA/RNA sequencing technology is being used in nearly 100 countries, for a range of biological research applications. These include large scale human genomics, cancer research, microbiology, plant science and environmental research.
Nanopore's portable MinION device, and desktop GridION and PromethION devices, are used in a broad range of scientific analyses, across human genetics, cancer research, agriculture, food safety, healthcare, and environmental insights.
Nanopore is backed by GIC, GT Healthcare Capital Partners, IP Group Plc, Amgen, Baillie Gifford, Temasek, Wellington Management, M&G Investments, IHC and others. The company raised £195M ($271M) in a new round on May 05, 2021. Tis brings Nanopore's total funding to £994.6M to date. The transaction valued the company at £2.48B post-money.
Oxford Nanopore Technologies went public on Sep 30, 2021. The company raised £524M from the listing with a valuation of £5B ($6.84B) at IPO.
